VANDERSON GERALDO ROCHA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
17 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 17
- Duffy null genotype or Fy(a-b-) phenotype are more accurate than self-declared race for diagnosing benign ethnic neutropenia in Brazilian population(2017) DINARDO, C. L.; KERBAUY, M. N.; SANTOS, T. C.; LIMA, W. M.; DEZAN, M. R.; OLIVEIRA, V. B.; MENDRONE-JUNIOR, A.; ROCHA, V.; VELLOSO, E. D. R. P.
conferenceObject Surveillance Functional Imaging Has Limited Role in Solitary Plasmacytomas: International Multi-Centre Study of Clinical Outcomes(2017) SHARPLEY, Faye A.; NEFFA, Pedro; PANITSAS, Fotis; KOTHARI, Jaimal; CUTTER, David; SZOR, Roberta Shcolnik; SUBESINGHE, Manil; MARTINEZ, Gracia; ROCHA, Vanderson; RAMASAMY, KarthikconferenceObject NIH Bayesian Score As a Stratification Tool in Sickle Cell Disease - Results from a Single Center Cohort in Brazil(2017) FONSECA, Guilherme Henrique Hencklain; GRACA, Lutu Ima Viana da; SOUZA, Rogerio; SUGANUMA, Liliana Mitie; ROCHA, Vanderson; GUALANDRO, Sandra Fatima- Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease in a Single Institution in Brazil. Reproducing Good Results with a Reduced Toxicity Regimen(2017) FERNANDES, Juliana Folloni; MANTOVANI, Luiz Fernando Alves Lima; VENANCIO, Angela Mandelli; DORNA, Mayra; PASTORINO, Antonio Carlos; VASCONCELOS, Dewton; NETO, Antonio Condino; MOURA, Ana Carla Augusto; COLLASSANTI, Maria Dulce; ZANICHELLI, Maria Aparecida; CARNEIRO-SAMPAIO, Magda; ROCHA, Vanderson G.; ODONE FILHO, Vicente
- Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies(2017) PAVIGLIANITI, Annalisa; RUGGERI, Annalisa; VOLT, Fernanda; SANZ, Guillermo; MILPIED, Noel; FURST, Sabine; ESQUIROL, Albert; ARCESE, William; PICARDI, Alessandra; FERRA, Christelle; IFRAH, Norbert; BOURHIS, Jean H.; RAJ, Kavita; BORNE, Peter A. von dem; SICA, Simona; MENARD, Anne-lise; BLOOR, Adrian; KENZEY, Chantal; GLUCKMAN, Eliane; ROCHA, VandersonA disease risk index (DRI) has been defined for stratifying heterogeneous cohorts of patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). This index defines 4 distinct groups with different outcomes, dividing patients by disease type and status and considering cytogenetics for acute myeloid leukaemia and myelodysplastic syndromes (MDS). Recently, the DRI has been refined to include rare diseases and improve MDS stratification by blast percentage and response to prior therapy. Previous reports on DRI include only a small number of UCBT recipients. The current study aims to determine the applicability of the DRI for patients undergoing unrelated cord blood transplantation (UCBT). We retrospectively analysed 2530 adults receiving UCBT between 2004 and 2014. Diagnosis was acute leukaemia (AL) in 66% of the cases. Overall survival (OS) at 2 years was 56 +/- 3% for patients with low DRI (n = 352), 46 +/- 1% for intermediate DRI (n = 1403), 28 +/- 2% for high (n = 489) and 20 +/- 4% for very high DRI (n = 109) (P < 0.001). In the multivariate model, DRI remained an independent risk factor for OS. Similar findings were observed for PFS and DRI. Our results show the applicability of DRI for stratifying UCBT recipients and confirm the prognostic value of this simple and robust tool in this setting.
conferenceObject Selecting between HLA-Matched Siblings and HLA- Haploidentical Related Donors for Acute Leukemia in the Era of Post-Transplant Cyclophosphamide: The Center for International Blood and Marrow Transplant Registry and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant(2017) ROBINSON, Tara M.; FUCHS, Ephraim J.; ZHANG, Mei-Jie; LABOPIN, Myriam; MARTIN, Andrew St.; KEESLER, Daniel A.; BLAISE, Didier; BASHEY, Asad; BOURHIS, Jean-Henri; CICERI, Fabio; CIUREA, Stefan O.; DEVINE, Steven M.; MOHTY, Mohamad; MCCURDY, Shannon R.; MILPIED, Noel; MCNIECE, Ian K.; ROCHA, Vanderson; ROMEE, Rizwan; SOCIE, Gerard; YAKOUB-AGHA, Ibrahim; SOIFFER, Robert J.; EAPEN, Mary; NAGLER, Arnon- RHD and RHCE genotyping by next-generation sequencing is an effective strategy to identify molecular variants within sickle cell disease patients(2017) DEZAN, Marcia R.; RIBEIRO, Ingrid Helena; OLIVEIRA, Valeria B.; VIEIRA, Juliana B.; GOMES, Francisco C.; FRANCO, Lucas A. M.; VARUZZA, Leonardo; RIBEIRO, Roberto; CHINOCA, Karen Ziza; LEVI, Jose Eduardo; KRIEGER, Jose Eduardo; PEREIRA, Alexandre Costa; GUALANDRO, Sandra F. M.; ROCHA, Vanderson G.; MENDRONE-JUNIOR, Alfredo; SABINO, Ester Cerdeira; DINARDO, Carla LuanaBackground: The complexity of Rh genetic variation among sickle cell disease (SCD) patients is high. Conventional molecular assays cannot identify all genetic variants already described for the RH locus as well as foresee novel alleles. Sequencing RHD and RHCE is indicated to broaden the search for Rh genetic variants. Aims: To standardize the Next Generation Sequencing (NGS) strategy to assertively identify Rh genetic variants among SCD patients with serologic suspicion of Rh variants and evaluate if it can improve the transfusion support. Methods: Thirty-five SCD patients with unexplained Rh antibodies were enrolled. A NGS-based strategy was developed to genotype RHD and RHCE using gene-specific primers. Genotype and serological data were compared. Results: Data obtained from the NGS-based assay were gene-specific. Ten and 25 variant RHD and RHCE alleles were identified, respectively. Among all cases of unexplained Rh antibodies, 62% had been inaccurately classified by serological analysis and, of these, 73.1% were considered as relevant, as were associated with increased risk of hemolytic reactions and shortage of units suitable for transfusion. Conclusion: The NGS assay designed to genotype RH coding regions was effective and accurate in identifying variants. The proposed strategy clarified the Rh phenotype of most patients, improving transfusion support.
- Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia(2017) NIKOLAJEVA, Olga; ROCHA, Vanderson; DANBY, Robert; RUGGERI, Annalisa; VOLT, Fernanda; BAUDOUX, Etienne; GOMEZ, Susana G.; KOEGLER, Gezine; LARGHERO, Jerome; LECCHI, Lucilla; MARTINEZ, Mar Sanchez; NAVARRETE, Cristina; POUTHIERS, Fabienne; QUEROL, Sergio; KENZEY, Chantal; SZYDLO, Richard; GLUCKMAN, Eliane; MADRIGAL, AlejandroSeveral studies have reported an impact of adult hematopoietic stem cell donor cytomegalovirus (CMV) serostatus on allogeneic hematopoietic cell transplantation outcomes. Limited data, however, are available on the impact of cord blood unit (CBU) CMV serostatus on allogeneic umbilical cord blood transplantation (UCBT) outcomes. We analyzed, retrospectively, the impact of CBU CMV serostatus on relapse incidence (RI) and 2-year nonrelapse mortality (NRM) of single-unit CBU transplantation for acute leukemia. Data from 1177 de novo acute leukemia pediatric and adult patients transplanted within European Group for Blood and Marrow Transplantation centers between 2000 and 2012 were analyzed. CBUs were provided by the European Cord Blood Banks. The median follow-up time for live patients was 59.9 months. The recipients of CMV-seropositive and -seronegative CBUs showed a comparable RI (33% versus 35%, respectively, P=.6) and 2-year cumulative incidence of NRM (31% versus 32%, respectively, P =.5). We conclude that CBU CMV serostatus did not influence RI and NRM in de novo acute leukemia patients after allo-UCBT and should not be included as a criteria for cord blood choice. (C) 2017 American Society for Blood and Marrow Transplantation.
conferenceObject Outcomes of Cord Blood Transplantation for Adult Patients with Hodgkin Lymphoma, a Eurocord and EBMT Lymphoma Working Party Study(2017) PAVIGLIANITI, Annalisa; TOZATTO-MAIO, Karina; ROCHA, Vanderson; GEHLKOPF, Eve; MILPIED, Noel; ESQUIROL, Albert; CHEVALLIER, Patrice; BLAISE, Didier; DAMAJ, Gandhi; NGUYEN-QUOC, Stephanie; CAHN, Jean Yves; ABECASIS, Manuel; ZUCKERMAN, Tsila; SCHOUTEN, Harry C.; GURMAN, Gunhan; RUBIO, Marie Therese; BEGUIN, Yves; CORRAL, Lucia Lopez; NAGLER, Arnon; SNOWDEN, John A.; YENER, Koc; MORDINI, Nicola; BONIFAZI, Francesca; FANIN, Renato; VOLT, Fernanda; KENZEY, Chantal; ROBINSON, Stephen; MONTOTO, Silvia; GLUCKMAN, Eliane; RUGGERI, Annalisa- Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission(2017) PAGE, Kristin M.; LABOPIN, Myriam; RUGGERI, Annalisa; MICHEL, Gerard; HEREDIA, Cristina Diaz de; O'BRIEN, Tracey; PICARDI, Alessandra; AYAS, Mouhab; BITTENCOURT, Henrique; VORA, Ajay J.; TROY, Jesse; BONFIM, Carmen; VOLT, Fernanda; GLUCKMAN, Eliane; BADER, Peter; KURTZBERG, Joanne; ROCHA, VandersonFor pediatric patients with acute lymphoblastic leukemia (ALL), relapse is an important cause of treatment failure after unrelated cord blood transplant (UCBT). Compared with other donor sources, relapse is similar or even reduced after UCBT despite less graft-versus-host disease (GVHD). We performed a retrospective analysis to identify risk factors associated with the 5-year cumulative incidence of relapse after UCBT. In this retrospective, registry-based study, we examined the outcomes of 640 children (<18 years) with ALL in first complete remission (CR1; n = 257, 40%) or second complete remission (CR2; n = 383, 60%) who received myeloablative conditioning followed by a single-unit UCBT from 2000 to 2012. Most received antithymocyte globulin (88%) or total body irradiation (TBI; 69%), and cord blood grafts were primarily mismatched at 1 (50%) or 2(+) (34%) HLA loci. Considering patients in CR1, the rates of 5-year overall survival (OS), leukemia-free survival (LFS), and relapse were 59%, 52%, and 23%, respectively. In multivariate analysis (MVA), acute GVHD (grades II to IV) and TBI protected against relapse. In patients in CR2, rates of 5-year OS, LFS, and the cumulative incidence of relapse were 46%, 44%, and 28%, respectively. In MVA, longer duration from diagnosis to UCBT >= 30 months) and TBI were associated with decreased relapse risk. Importantly, receiving a fully HLA matched graft was a strong risk factor for increased relapse in MVA. An exploratory analysis of all 640 patients supported the important association between the presence of acute GVHD and less relapse but also demonstrated an increased risk of nonrelapse mortality. In conclusion, the impact of GVHD as a graft-versus-leukemia marker is evident in pediatric ALL after UCBT. Strategies that promote graft-versus-leukemia while harnessing GVHD should be further investigated. (C) 2017 American Society for Blood and Marrow Transplantation.